Science Explorer Back to mapMap
Discussion
Company · San Carlos · United States

Cellerant Therapeutics (United States)

cellerant.comROR OpenAlex
Research works
32
▼ 14% vs 2018-21
Citations
1.1k
35.2 per fractional work
Top-10% rate
18.1%
all institutions 10.0%
Open access
52%
world 40%
International
13%
world 18%
Cellerant Therapeutics (United States)

Not ranked overall: Cellerant Therapeutics (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Cellerant Therapeutics (United States) work in?

In all years, 50% of research at Cellerant Therapeutics (United States) is in Health Sciences, 41% in Life Sciences. Its largest fields are Medicine (49%), Biochemistry, Genetics and Molecular Biology (31%), Immunology and Microbiology (9%). It does 2.1× the world's share of Life Sciences.

Health Sciences: 16 fractional works · 50.3% of its workMedicine: 16 fractional works · 49.2% of its workOncology: 3 fractional works · 10.3% of its workHematology: 3 fractional works · 9.2% of its workRadiology, Nuclear Medicine and Imaging: 2 fractional works · 6.6% of its workPulmonary and Respiratory Medicine: 1 fractional works · 3.8% of its workRheumatology: 1 fractional works · 3.5% of its workGenetics: 1 fractional works · 3.1% of its workSurgery: 1 fractional works · 2.1% of its workCardiology and Cardiovascular Medicine: 1 fractional works · 1.8% of its workEpidemiology: 0 fractional works · 1.2% of its workRehabilitation: 0 fractional works · 1.2% of its workPublic Health, Environmental and Occupational Health: 0 fractional works · 1.1% of its workInfectious Diseases: 0 fractional works · 1.0% of its workUrology: 0 fractional works · 1.0% of its workNeurology: 0 fractional works · 0.5% of its workHepatology: 0 fractional works · 0.4% of its workPathology and Forensic Medicine: 0 fractional works · 0.4% of its workOphthalmology: 0 fractional works · 0.3% of its workPharmacology: 0 fractional works · 0.3% of its workPediatrics, Perinatology and Child Health: 0 fractional works · 0.3% of its workEmergency Medicine: 0 fractional works · 0.3% of its workGeriatrics and Gerontology: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.4% of its workHealth Professions: 0 fractional works · 0.6% of its workHealth Information Management: 0 fractional works · 0.4% of its workSmaller subfields together: 0 fractional works · 0.2% of its workDentistry: 0 fractional works · 0.4% of its workNursing: 0 fractional works · 0.1% of its workLife Sciences: 13 fractional works · 41.1% of its workBiochemistry, Genetics and Molecular Biology: 10 fractional works · 30.9% of its workMolecular Biology: 7 fractional works · 22.5% of its workCancer Research: 1 fractional works · 4.1% of its workBiotechnology: 1 fractional works · 1.7% of its workCell Biology: 0 fractional works · 1.2% of its workGenetics: 0 fractional works · 0.8% of its workBiophysics: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.2% of its workImmunology and Microbiology: 3 fractional works · 9.3% of its workImmunology: 3 fractional works · 9.3% of its workNeuroscience: 0 fractional works · 0.9% of its workDevelopmental Neuroscience: 0 fractional works · 0.5% of its workCellular and Molecular Neuroscience: 0 fractional works · 0.3% of its workPhysical Sciences: 2 fractional works · 7.2% of its workEngineering: 1 fractional works · 3.8% of its workBiomedical Engineering: 1 fractional works · 3.8% of its workChemistry: 1 fractional works · 2.3% of its workOrganic Chemistry: 1 fractional works · 2.3% of its workMaterials Science: 0 fractional works · 0.8% of its workMaterials Chemistry: 0 fractional works · 0.5% of its workBiomaterials: 0 fractional works · 0.3% of its workMathematics: 0 fractional works · 0.3% of its workStatistics and Probability: 0 fractional works · 0.3% of its workEnvironmental Science: 0 fractional works · 0.0% of its workSocial Sciences: 0 fractional works · 1.4% of its workEconomics, Econometrics and Finance: 0 fractional works · 0.8% of its workEconomics and Econometrics: 0 fractional works · 0.8% of its workPsychology: 0 fractional works · 0.3% of its workExperimental and Cognitive Psychology: 0 fractional works · 0.3% of its workDecision Sciences: 0 fractional works · 0.2% of its workInformation Systems and Management: 0 fractional works · 0.2% of its workALL ITS WORKCellerantTherapeutics…32fractional works, all years
Life Sciences41%Physical Sciences7%Health Sciences50%Social Sciences1%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 15 fields, with their numbers
    1. Medicine1649.2%
    2. Health Professions00.6%
    3. Dentistry00.4%
    4. Nursing00.1%
    1. Biochemistry, Genetics and Molecular Biology1030.9%
    2. Immunology and Microbiology39.3%
    3. Neuroscience00.9%
    1. Engineering13.8%
    2. Chemistry12.3%
    3. Materials Science00.8%
    4. Mathematics00.3%
    5. Environmental Science00.0%
    1. Economics, Econometrics and Finance00.8%
    2. Psychology00.3%
    3. Decision Sciences00.2%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 9.27× its world share, 3 worksBiochemistry, Geneti…Immunology and Microbiology: 0.79× its world share, 0 worksImmunology and Micro…Chemistry: 2.54× its world share, 0 worksChemistryEnvironmental Science: 0.02× its world share, 0 worksEnvironmental ScienceMaterials Science: 0.15× its world share, 0 worksMaterials ScienceDentistry: 0.49× its world share, 0 worksDentistryHealth Professions: 0.83× its world share, 0 worksHealth ProfessionsMedicine: 2.17× its world share, 3 worksMedicineDecision Sciences: 0.99× its world share, 0 worksDecision Sciences1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Biochemistry, Genetics and Molecular Biology, 9.3×. Every wedge is a field page.

All 9 fields, with their numbers
  1. Biochemistry, Genetics and Molecular Biology9.27×3 works
  2. Chemistry2.54×0 works
  3. Medicine2.17×3 works
  4. Decision Sciences0.99×0 works
  5. Health Professions0.83×0 works
  6. Immunology and Microbiology0.79×0 works
  7. Dentistry0.49×0 works
  8. Materials Science0.15×0 works
  9. Environmental Science0.02×0 works

Who are the top researchers at Cellerant Therapeutics (United States)?

Ranked on the quality score, T. Fong lead among researchers whose main affiliation is Cellerant Therapeutics (United States).

  1. 1 T. Fong United States · #4,600,753 worldwide 265 citations · 20 works
All ranked researchers at Cellerant Therapeutics (United States)

What are the most cited papers from Cellerant Therapeutics (United States)?

The most cited paper from Cellerant Therapeutics (United States) is "Targeting renal cell carcinoma with a HIF-2 antagonist" (Wenfang Chen et al., 2016), with 744 citations. Next come "On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models" (469) and "Ly6d marks the earliest stage of B-cell specification and identifies the branchpoint between B-cell and T-cell development" (324).

Most cited papers
#PaperReleasedCitations
1 Targeting renal cell carcinoma with a HIF-2 antagonist Wenfang Chen et al. · Nature Open access 5 Sep 2016 744
2 On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models Hyejin Cho, Xinlin Du, James P. Rizzi et al. · Nature Open access 5 Sep 2016 469
3 Ly6d marks the earliest stage of B-cell specification and identifies the branchpoint between B-cell and T-cell development Matthew A. Inlay, Deepta Bhattacharya, Debashis Sahoo et al. · Genes & Development Open access 15 Oct 2009 324
4 Intratumoral immunotherapy using platelet-cloaked nanoparticles enhances antitumor immunity in solid tumors Baharak Bahmani, Hua Gong, Brian T. Luk et al. · Nature Communications Open access 31 Mar 2021 303
5 Identification of the earliest natural killer cell–committed progenitor in murine bone marrow John W. Fathman, Deepta Bhattacharya, Matthew A. Inlay et al. · Blood Open access 20 Sep 2011 214
All 44 most cited papers, with filters and sorting

Which keywords describe research at Cellerant Therapeutics (United States)?

By fractional works in all years, weighted toward what it does more of than the world: Cancer, Inflammation, Mesenchymal Stem Cells, Glycosylation, Chemotherapy, Tumor Microenvironment, Immunotherapy and Hematopoietic Stem Cells.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 31 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 31 words, with their numbers
  1. Cancer4▲ 8.9×9 topics
  2. Inflammation4▲ 5.4×16 topics
  3. Mesenchymal Stem Cells2▲ 59×3 topics
  4. Chemotherapy2▲ 9.1×8 topics
  5. Glycosylation2▲ 30×2 topics
  6. Oxidative Stress2▲ 3.6×10 topics
  7. Tumor Microenvironment2▲ 18×4 topics
  8. Immunotherapy2▲ 8.8×5 topics
  9. Hematopoietic Stem Cells2▲ 54×2 topics
  10. Toll-like Receptors2▲ 29×3 topics
  11. Genomic Instability2▲ 37×2 topics
  12. Monoclonal Antibodies1▲ 31×2 topics
  13. Bone Marrow Niche1▲ 119×1 topic
  14. Fc Receptors1▲ 42×1 topic
  15. Graft-versus-Host Disease1▲ 119×1 topic
  16. HIF-11▲ 56×1 topic
  17. Hemostasis1▲ 28×4 topics
  18. Metabolism1▲ 6.3×4 topics
  19. Regeneration1▲ 22×3 topics
  20. Therapeutic Antibodies1▲ 33×1 topic
  21. Warburg Effect1▲ 56×1 topic
  22. Angiogenesis1▲ 9.0×5 topics
  23. Cancer Immunotherapy1▲ 26×2 topics
  24. Drug Discovery1▲ 9.6×4 topics
  25. Gene Therapy1▲ 14×3 topics
  26. Immunity1▲ 11×2 topics
  27. Microfluidics1▲ 39×1 topic
  28. Particle Separation1▲ 95×1 topic
  29. Tumor Regression1▲ 40×2 topics
  30. Prophylaxis1▲ 23×2 topics
  31. Radiotherapy1▲ 8.5×4 topics

Which research topics does Cellerant Therapeutics (United States) publish most on?

By volume in 2022-now: DNA Repair Mechanisms, Venomous Animal Envenomation and Studies, Mitochondrial Function and Pathology and Chemotherapy-induced cardiotoxicity and mitigation.

DNA Repair Mechanisms1DNA Repair Mechanisms: 1 fractional worksVenomous Animal Envenomation and Studies: 0 fractional worksMitochondrial Function and Pathology: 0 fractional worksChemotherapy-induced cardiotoxicity and mitigation: 0 fractional worksHeat shock proteins rese…0Heat shock proteins research: 0 fractional worksNuclear Structure and Function: 0 fractional worksBiochemical and Molecular Research: 0 fractional worksHIV/AIDS drug developmen…0HIV/AIDS drug development and treatment: 0 fractional worksATP Synthase and ATPases Research: 0 fractional worksEffects of Radiation Exposure: 0 fractional works
Molecular BiologyGeneticsCardiology and Cardiovascular MedicineInfectious Diseases1 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 DNA Repair Mechanisms Molecular Biology 1 works
  2. 2 Venomous Animal Envenomation and Studies Genetics 0 works
  3. 3 Mitochondrial Function and Pathology Molecular Biology 0 works
  4. 4 Chemotherapy-induced cardiotoxicity and mitigation Cardiology and Cardiovascular Medicine 0 works
  5. 5 Heat shock proteins research Molecular Biology 0 works
  6. 6 Nuclear Structure and Function Molecular Biology 0 works
  7. 7 Biochemical and Molecular Research Molecular Biology 0 works
  8. 8 HIV/AIDS drug development and treatment Infectious Diseases 0 works
  9. 9 ATP Synthase and ATPases Research Molecular Biology 0 works
  10. 10 Effects of Radiation Exposure Radiology, Nuclear Medicine and Imaging 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available51.5%not open48.5%

World: 40% of research is openly available.

with international co-authors12.8%domestic only87.2%

World: 18% is written across borders.

How has Cellerant Therapeutics (United States)'s research output changed?

Output in 2022-2025 was 14% lower than in 2018-2021.

still counting20052010201520202025
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Cellerant Therapeutics (United States) as a percentage of every work published that year, 0.000014% in 2024.

still counting0.000050%0.00010%0.00015%Cellerant Therapeutics (United States)0.000045% in 202520102020

Fractional works of Cellerant Therapeutics (United States) over all fractional works that year. How the balance of science has shifted.

Other research institutions in San Carlos

All research institutions in San Carlos

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Cellerant Therapeutics (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.